Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 67
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for BCRX

Stock Name	BioCryst Pharmaceuticals Inc
Ticker	BCRX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US09058V1035
LEI	549300Z0INP1Z5NP6J59

Show aggregate BCRX holdings

News associated with BCRX

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Analysts: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price […] - 2025-09-05 04:29:03
Headlands Technologies LLC Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,219 shares of the biotechnology company’s stock, valued at approximately $32,000. A number of […] - 2025-08-14 04:45:23
New Age Alpha Advisors LLC Takes $62,000 Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): New Age Alpha Advisors LLC acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,235 shares of the biotechnology company’s stock, valued at approximately $62,000. A number of other institutional […] - 2025-08-12 05:00:48
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Moderate Buy” by Analysts: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year […] - 2025-08-11 02:28:49
XTX Topco Ltd Acquires 66,320 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): XTX Topco Ltd increased its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 314.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 87,389 shares of the biotechnology company’s stock after purchasing an additional 66,320 shares during the […] - 2025-08-06 05:57:13
Mackenzie Financial Corp Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Mackenzie Financial Corp grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 37.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 116,258 shares of the biotechnology company’s stock after purchasing an additional 31,596 shares during the period. […] - 2025-08-06 05:18:53
Universal Beteiligungs und Servicegesellschaft mbH Makes New $125,000 Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund bought 16,704 shares of the biotechnology company’s stock, valued at approximately $125,000. Other hedge funds have also modified their […] - 2025-08-06 04:28:49
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Strong Earnings: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) shares gapped up before the market opened on Monday following a stronger than expected earnings report. The stock had previously closed at $7.95, but opened at $9.14. BioCryst Pharmaceuticals shares last traded at $8.32, with a volume of 2,333,940 shares traded. The biotechnology company reported $0.15 earnings […] - 2025-08-06 02:13:11
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Cerity Partners LLC: Cerity Partners LLC boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 203.6% in the 1st quarter, Holdings Channel reports. The firm owned 36,410 shares of the biotechnology company’s stock after purchasing an additional 24,418 shares during the period. Cerity Partners LLC’s holdings in BioCryst Pharmaceuticals were worth $273,000 at the end […] - 2025-07-28 04:46:48
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen: BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday. A number of other research firms have also recently commented on BCRX. Needham & Company LLC restated a “buy” rating […] - 2025-07-28 02:18:50
Y Intercept Hong Kong Ltd Buys 73,242 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Y Intercept Hong Kong Ltd grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 106.7% in the 1st quarter, Holdings Channel.com reports. The firm owned 141,865 shares of the biotechnology company’s stock after purchasing an additional 73,242 shares during the period. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth […] - 2025-07-25 06:52:53
Bank of America Raises BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $15.00: BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price raised by equities research analysts at Bank of America from $13.00 to $15.00 in a note issued to investors on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s target price indicates a potential upside of […] - 2025-07-03 04:38:51
Wedbush Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock: BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its price target raised by research analysts at Wedbush from $16.00 to $18.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s price target would indicate a potential upside of 100.00% from the company’s current price. […] - 2025-07-02 02:32:50
BioCryst Pharmaceuticals (NASDAQ:BCRX) Earns “Outperform” Rating from Royal Bank Of Canada: BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “outperform” rating restated by research analysts at Royal Bank Of Canada in a report released on Monday,Benzinga reports. They currently have a $13.00 price objective on the biotechnology company’s stock. Royal Bank Of Canada’s price objective would indicate a potential upside of 44.44% from the […] - 2025-07-02 02:32:47
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Acquired by SG Americas Securities LLC: SG Americas Securities LLC raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 5.2% during the first quarter, HoldingsChannel reports. The fund owned 43,496 shares of the biotechnology company’s stock after acquiring an additional 2,146 shares during the quarter. SG Americas Securities LLC’s holdings in BioCryst Pharmaceuticals were worth $326,000 […] - 2025-06-26 04:58:58
Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Target Price at $16.56: Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year […] - 2025-06-25 02:44:54
Peek Under The Hood: FHLC Has 21% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-20 08:15:40
Millennium Management LLC Sells 634,095 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Millennium Management LLC cut its holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 44.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 790,105 shares of the biotechnology company’s stock after selling 634,095 shares during the quarter. Millennium Management LLC’s holdings […] - 2025-05-28 04:56:50
ProShare Advisors LLC Has $511,000 Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): ProShare Advisors LLC increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,004 shares of the biotechnology company’s stock after purchasing an additional 16,732 shares during the period. ProShare […] - 2025-05-27 05:36:51
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Bought by Man Group plc: Man Group plc increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 46.3% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 89,954 shares of the biotechnology company’s stock after purchasing an additional 28,481 shares during the period. Man Group […] - 2025-05-26 05:01:05
Wall Street Zen Upgrades BioCryst Pharmaceuticals (NASDAQ:BCRX) to “Strong-Buy”: Wall Street Zen upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) from a buy rating to a strong-buy rating in a research note published on Thursday. BCRX has been the subject of several other research reports. JPMorgan Chase & Co. lifted their target price on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the […] - 2025-05-23 04:32:52
Lazard Asset Management LLC Buys 65,420 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Lazard Asset Management LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 68.1% during the fourth quarter, Holdings Channel reports. The fund owned 161,516 shares of the biotechnology company’s stock after acquiring an additional 65,420 shares during the quarter. Lazard Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $1,214,000 as […] - 2025-05-20 06:00:50
The Manufacturers Life Insurance Company Cuts Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): The Manufacturers Life Insurance Company decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 65.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 103,531 shares of the biotechnology company’s stock after selling 195,621 shares during the period. The Manufacturers Life Insurance Company’s holdings in […] - 2025-05-15 04:45:06
10,670 Shares in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Bought by Raymond James Financial Inc.: Raymond James Financial Inc. purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,670 shares of the biotechnology company’s stock, valued at approximately $80,000. Several other institutional […] - 2025-05-14 04:26:53
Mariner LLC Grows Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Mariner LLC lifted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 32.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,258 shares of the biotechnology company’s stock after purchasing an additional 3,224 shares during the quarter. […] - 2025-05-09 05:08:42
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $17.00 Price Target at Needham & Company LLC: BioCryst Pharmaceuticals (NASDAQ:BCRX – Free Report) had its price target lifted by Needham & Company LLC from $15.00 to $17.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock. Other equities research analysts have also issued research reports about the stock. Wedbush assumed coverage on […] - 2025-05-09 04:26:42
Tudor Investment Corp ET AL Makes New Investment in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Tudor Investment Corp ET AL bought a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 99,450 shares of the biotechnology company’s stock, valued at approximately $748,000. A number of other institutional […] - 2025-05-08 06:44:51
JPMorgan Chase & Co. Boosts BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $13.00: BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) had its target price lifted by JPMorgan Chase & Co. from $10.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 28.97% […] - 2025-05-08 05:04:48
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Earnings Beat: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report)’s stock price gapped up before the market opened on Monday after the company announced better than expected quarterly earnings. The stock had previously closed at $8.93, but opened at $9.80. BioCryst Pharmaceuticals shares last traded at $10.03, with a volume of 5,915,215 shares changing hands. The biotechnology […] - 2025-05-07 02:20:57
Investors Buy Large Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock investors acquired 2,675 call options on the company. This represents an increase of approximately 174% compared to the average daily volume of 975 call options. BioCryst Pharmaceuticals Price Performance Shares of BCRX stock opened at […] - 2025-05-07 02:20:55

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) BCRX holdings

Date	Number of BCRX Shares Held	Base Market Value of BCRX Shares	Local Market Value of BCRX Shares	Change in BCRX Shares Held	Change in BCRX Base Value	Current Price per BCRX Share Held	Previous Price per BCRX Share Held
2025-12-18 (Thursday)	158,135	USD 1,152,804	USD 1,152,804	0	USD 25,301	USD 7.29	USD 7.13
2025-12-17 (Wednesday)	158,135	USD 1,127,503	USD 1,127,503	-1,815	USD -67,324	USD 7.13	USD 7.47
2025-12-16 (Tuesday)	159,950	USD 1,194,827	USD 1,194,827	-363	USD -21,949	USD 7.47	USD 7.59
2025-12-15 (Monday)	160,313	USD 1,216,776	USD 1,216,776	726	USD 8,702	USD 7.59	USD 7.57
2025-12-12 (Friday)	159,587	USD 1,208,074	USD 1,208,074	0	USD -1,595	USD 7.57	USD 7.58
2025-12-11 (Thursday)	159,587	USD 1,209,669	USD 1,209,669	6,662	USD 38,263	USD 7.58	USD 7.66
2025-12-10 (Wednesday)	152,925	USD 1,171,406	USD 1,171,406	0	USD 3,059	USD 7.66	USD 7.64
2025-12-09 (Tuesday)	152,925	USD 1,168,347	USD 1,168,347	0	USD -9,176	USD 7.64	USD 7.7
2025-12-08 (Monday)	152,925	USD 1,177,523	USD 1,177,523	0	USD 16,822	USD 7.7	USD 7.59
2025-12-05 (Friday)	152,925	USD 1,160,701	USD 1,160,701	0	USD -36,702	USD 7.59	USD 7.83
2025-12-04 (Thursday)	152,925	USD 1,197,403	USD 1,197,403	6,960	USD 51,578	USD 7.83	USD 7.85
2025-12-03 (Wednesday)	145,965	USD 1,145,825	USD 1,145,825	0	USD 100,716	USD 7.85	USD 7.16
2025-12-02 (Tuesday)	145,965	USD 1,045,109	USD 1,045,109	5,235	USD 41,704	USD 7.16	USD 7.13
2025-12-01 (Monday)	140,730	USD 1,003,405	USD 1,003,405	0	USD -7,036	USD 7.13	USD 7.18

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of BCRX by Blackrock for IE00BDZVHG35

Show aggregate share trades of BCRX

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-12-17 SELL -1,815 7.570 7.110 7.156 USD -12,988 8.24 Profit of 1,966 on sale
2025-12-16 SELL -363 7.700 7.360 7.394 USD -2,684 8.24 Profit of 308 on sale
2025-12-15 BUY 726 7.915 7.435 7.483 USD 5,433 8.25
2025-12-11 BUY 6,662 7.770 7.540 7.563 USD 50,385 8.25
2025-12-04 BUY 6,960 7.830* 8.27
2025-12-02 BUY 5,235 7.300 7.115 7.133 USD 37,344 8.27
2025-11-28 BUY 349 7.225 7.060 7.077 USD 2,470 8.28
2025-11-26 BUY 1,047 7.140 6.810 6.843 USD 7,165 8.30
2025-11-26 BUY 1,047 7.140 6.810 6.843 USD 7,165 8.30
2025-11-25 BUY 1,745 7.010 6.705 6.735 USD 11,753 8.30
2025-11-24 BUY 350 7.050 6.710 6.744 USD 2,360 8.31
2025-11-20 SELL -1,392 7.090 6.895 6.914 USD -9,625 8.32 Profit of 1,962 on sale
2025-11-19 BUY 348 7.071 6.735 6.769 USD 2,355 8.33
2025-11-18 BUY 2,088 7.125 6.970 6.985 USD 14,586 8.34
2025-11-17 BUY 696 7.205 7.010 7.030 USD 4,893 8.34
2025-11-14 BUY 348 7.185 6.860 6.893 USD 2,399 8.35
2025-11-12 BUY 348 7.315 7.140 7.158 USD 2,491 8.37
2025-11-10 BUY 346 7.270 7.080 7.099 USD 2,456 8.38
2025-11-06 BUY 346 7.150 6.870 6.898 USD 2,387 8.39
2025-11-04 BUY 348 6.895 6.510 6.549 USD 2,279 8.41
2025-10-30 BUY 1,740 7.430 7.215 7.237 USD 12,592 8.43
2025-10-29 BUY 696 7.310 7.370 7.364 USD 5,125 8.43
2025-10-22 SELL -1,388 7.080 7.160 7.152 USD -9,927 8.47 Profit of 1,827 on sale
2025-10-20 BUY 694 6.930 6.930 6.930 USD 4,809 8.49
2025-10-17 BUY 1,733 6.630 6.680 6.675 USD 11,568 8.50
2025-10-15 BUY 2,760 6.810 6.880 6.873 USD 18,969 8.51
2025-10-03 BUY 2,436 7.150 7.470 7.438 USD 18,119 8.53
2025-10-02 BUY 348 7.330 7.420 7.411 USD 2,579 8.53
2025-09-30 BUY 696 7.590 7.620 7.617 USD 5,301 8.55
2025-09-26 BUY 696 7.630 7.730 7.720 USD 5,373 8.56
2025-09-25 BUY 696 7.650 7.890 7.866 USD 5,475 8.56
2025-09-18 BUY 364 7.960 7.970 7.969 USD 2,901 8.57
2025-09-17 BUY 1,095 7.700 7.990 7.961 USD 8,717 8.57
2025-09-11 SELL -364 8.070 8.130 8.124 USD -2,957 8.58 Profit of 166 on sale
2025-09-10 BUY 728 8.010 8.100 8.091 USD 5,890 8.58
2025-07-17 SELL -724 8.700 8.720 8.718 USD -6,312 8.59 Loss of -95 on sale
2025-07-11 SELL -2,904 8.760 8.870 8.859 USD -25,727 8.58 Loss of -802 on sale
2025-07-02 BUY 19,965 9.020 9.170 9.155 USD 182,780 8.57
2025-06-25 BUY 724 9.740 10.020 9.992 USD 7,234 8.55
2025-06-20 BUY 2,655 10.100 10.150 10.145 USD 26,935 8.52
2025-06-11 BUY 708 10.610 11.070 11.024 USD 7,805 8.43
2025-06-10 BUY 708 11.010 11.220 11.199 USD 7,929 8.41
2025-06-04 SELL -354 11.040 11.310 11.283 USD -3,994 8.33 Loss of -1,047 on sale
2025-04-23 BUY 354 7.960 8.180 8.158 USD 2,888 7.84
2025-04-10 SELL -2,832 6.410 6.580 6.563 USD -18,586 7.91 Profit of 3,803 on sale
2025-04-08 SELL -354 6.470 7.080 7.019 USD -2,485 7.94 Profit of 324 on sale
2025-04-07 SELL -354 6.790 7.050 7.024 USD -2,486 7.95 Profit of 327 on sale
2025-04-04 SELL -1,775 6.830 7.180 7.145 USD -12,682 7.96 Profit of 1,450 on sale
2025-04-01 BUY 4,478 7.250 7.490 7.466 USD 33,433 7.98
2025-03-31 SELL -1,035 7.500 7.710 7.689 USD -7,958 7.98 Profit of 304 on sale
2025-03-21 BUY 5,375 7.980 8.100 8.088 USD 43,473 7.99
2025-03-14 SELL -5,264 7.700 7.740 7.736 USD -40,722 8.01 Profit of 1,435 on sale
2025-03-07 SELL -656 7.690 7.970 7.942 USD -5,210 8.04 Profit of 65 on sale
2025-03-04 SELL -328 8.310 8.390 8.382 USD -2,749 8.04 Loss of -112 on sale
2025-02-25 BUY 658 8.280 8.440 8.424 USD 5,543 8.00
2025-02-19 SELL -327 9.390 9.480 9.471 USD -3,097 7.93 Loss of -505 on sale
2025-02-13 BUY 981 8.820 8.900 8.892 USD 8,723 7.83
2025-02-12 BUY 327 8.780 9.000 8.978 USD 2,936 7.81
2025-02-11 BUY 1,308 8.990 9.000 8.999 USD 11,771 7.79
2024-12-30 SELL -13,012 7.530 7.710 7.692 USD -100,088 7.67 Loss of -300 on sale
2024-11-18 SELL -5,445 7.060 7.140 7.132 USD -38,834 7.88 Profit of 4,095 on sale
2024-11-08 SELL -363 7.780 7.840 7.834 USD -2,844 7.90 Profit of 23 on sale
2024-10-30 BUY 3,476 8.370 8.370 8.370 USD 29,094 7.99
2024-10-21 SELL -354 7.520 7.660 7.646 USD -2,707 0.00 Loss of -2,707 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-12-17	SELL	-1,815	7.570	7.110	7.156	USD -12,988	8.24 Profit of 1,966 on sale
2025-12-16	SELL	-363	7.700	7.360	7.394	USD -2,684	8.24 Profit of 308 on sale
2025-12-15	BUY	726	7.915	7.435	7.483	USD 5,433	8.25
2025-12-11	BUY	6,662	7.770	7.540	7.563	USD 50,385	8.25
2025-12-04	BUY	6,960			7.830*		8.27
2025-12-02	BUY	5,235	7.300	7.115	7.133	USD 37,344	8.27
2025-11-28	BUY	349	7.225	7.060	7.077	USD 2,470	8.28
2025-11-26	BUY	1,047	7.140	6.810	6.843	USD 7,165	8.30
2025-11-26	BUY	1,047	7.140	6.810	6.843	USD 7,165	8.30
2025-11-25	BUY	1,745	7.010	6.705	6.735	USD 11,753	8.30
2025-11-24	BUY	350	7.050	6.710	6.744	USD 2,360	8.31
2025-11-20	SELL	-1,392	7.090	6.895	6.914	USD -9,625	8.32 Profit of 1,962 on sale
2025-11-19	BUY	348	7.071	6.735	6.769	USD 2,355	8.33
2025-11-18	BUY	2,088	7.125	6.970	6.985	USD 14,586	8.34
2025-11-17	BUY	696	7.205	7.010	7.030	USD 4,893	8.34
2025-11-14	BUY	348	7.185	6.860	6.893	USD 2,399	8.35
2025-11-12	BUY	348	7.315	7.140	7.158	USD 2,491	8.37
2025-11-10	BUY	346	7.270	7.080	7.099	USD 2,456	8.38
2025-11-06	BUY	346	7.150	6.870	6.898	USD 2,387	8.39
2025-11-04	BUY	348	6.895	6.510	6.549	USD 2,279	8.41
2025-10-30	BUY	1,740	7.430	7.215	7.237	USD 12,592	8.43
2025-10-29	BUY	696	7.310	7.370	7.364	USD 5,125	8.43
2025-10-22	SELL	-1,388	7.080	7.160	7.152	USD -9,927	8.47 Profit of 1,827 on sale
2025-10-20	BUY	694	6.930	6.930	6.930	USD 4,809	8.49
2025-10-17	BUY	1,733	6.630	6.680	6.675	USD 11,568	8.50
2025-10-15	BUY	2,760	6.810	6.880	6.873	USD 18,969	8.51
2025-10-03	BUY	2,436	7.150	7.470	7.438	USD 18,119	8.53
2025-10-02	BUY	348	7.330	7.420	7.411	USD 2,579	8.53
2025-09-30	BUY	696	7.590	7.620	7.617	USD 5,301	8.55
2025-09-26	BUY	696	7.630	7.730	7.720	USD 5,373	8.56
2025-09-25	BUY	696	7.650	7.890	7.866	USD 5,475	8.56
2025-09-18	BUY	364	7.960	7.970	7.969	USD 2,901	8.57
2025-09-17	BUY	1,095	7.700	7.990	7.961	USD 8,717	8.57
2025-09-11	SELL	-364	8.070	8.130	8.124	USD -2,957	8.58 Profit of 166 on sale
2025-09-10	BUY	728	8.010	8.100	8.091	USD 5,890	8.58
2025-07-17	SELL	-724	8.700	8.720	8.718	USD -6,312	8.59 Loss of -95 on sale
2025-07-11	SELL	-2,904	8.760	8.870	8.859	USD -25,727	8.58 Loss of -802 on sale
2025-07-02	BUY	19,965	9.020	9.170	9.155	USD 182,780	8.57
2025-06-25	BUY	724	9.740	10.020	9.992	USD 7,234	8.55
2025-06-20	BUY	2,655	10.100	10.150	10.145	USD 26,935	8.52
2025-06-11	BUY	708	10.610	11.070	11.024	USD 7,805	8.43
2025-06-10	BUY	708	11.010	11.220	11.199	USD 7,929	8.41
2025-06-04	SELL	-354	11.040	11.310	11.283	USD -3,994	8.33 Loss of -1,047 on sale
2025-04-23	BUY	354	7.960	8.180	8.158	USD 2,888	7.84
2025-04-10	SELL	-2,832	6.410	6.580	6.563	USD -18,586	7.91 Profit of 3,803 on sale
2025-04-08	SELL	-354	6.470	7.080	7.019	USD -2,485	7.94 Profit of 324 on sale
2025-04-07	SELL	-354	6.790	7.050	7.024	USD -2,486	7.95 Profit of 327 on sale
2025-04-04	SELL	-1,775	6.830	7.180	7.145	USD -12,682	7.96 Profit of 1,450 on sale
2025-04-01	BUY	4,478	7.250	7.490	7.466	USD 33,433	7.98
2025-03-31	SELL	-1,035	7.500	7.710	7.689	USD -7,958	7.98 Profit of 304 on sale
2025-03-21	BUY	5,375	7.980	8.100	8.088	USD 43,473	7.99
2025-03-14	SELL	-5,264	7.700	7.740	7.736	USD -40,722	8.01 Profit of 1,435 on sale
2025-03-07	SELL	-656	7.690	7.970	7.942	USD -5,210	8.04 Profit of 65 on sale
2025-03-04	SELL	-328	8.310	8.390	8.382	USD -2,749	8.04 Loss of -112 on sale
2025-02-25	BUY	658	8.280	8.440	8.424	USD 5,543	8.00
2025-02-19	SELL	-327	9.390	9.480	9.471	USD -3,097	7.93 Loss of -505 on sale
2025-02-13	BUY	981	8.820	8.900	8.892	USD 8,723	7.83
2025-02-12	BUY	327	8.780	9.000	8.978	USD 2,936	7.81
2025-02-11	BUY	1,308	8.990	9.000	8.999	USD 11,771	7.79
2024-12-30	SELL	-13,012	7.530	7.710	7.692	USD -100,088	7.67 Loss of -300 on sale
2024-11-18	SELL	-5,445	7.060	7.140	7.132	USD -38,834	7.88 Profit of 4,095 on sale
2024-11-08	SELL	-363	7.780	7.840	7.834	USD -2,844	7.90 Profit of 23 on sale
2024-10-30	BUY	3,476	8.370	8.370	8.370	USD 29,094	7.99
2024-10-21	SELL	-354	7.520	7.660	7.646	USD -2,707	0.00 Loss of -2,707 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BCRX

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	564,076	78,653	998,534	56.5%
2025-09-18	249,046	5,213	665,741	37.4%
2025-09-17	626,535	0	1,344,624	46.6%
2025-09-16	416,542	0	849,250	49.0%
2025-09-15	513,698	873	1,366,168	37.6%
2025-09-12	336,394	240	1,653,913	20.3%
2025-09-11	343,166	700	941,865	36.4%
2025-09-10	481,873	5,684	1,056,285	45.6%
2025-09-09	312,252	2,013	901,725	34.6%
2025-09-08	209,980	19,598	510,102	41.2%
2025-09-05	321,726	39,760	1,095,983	29.4%
2025-09-04	145,255	16,436	438,747	33.1%
2025-09-03	582,145	62,912	1,717,145	33.9%
2025-09-02	351,305	481	941,300	37.3%
2025-08-29	191,767	4,400	800,585	24.0%
2025-08-28	420,801	0	745,725	56.4%
2025-08-27	178,401	0	405,141	44.0%
2025-08-26	253,850	0	558,420	45.5%
2025-08-25	406,114	0	839,313	48.4%
2025-08-22	192,262	0	573,421	33.5%
2025-08-21	221,221	0	458,557	48.2%
2025-08-20	131,166	0	427,344	30.7%
2025-08-19	146,809	0	764,932	19.2%
2025-08-18	305,880	0	716,730	42.7%
2025-08-15	228,075	155	881,323	25.9%
2025-08-14	525,213	0	1,005,235	52.2%
2025-08-13	329,649	0	1,231,192	26.8%
2025-08-12	401,217	0	894,029	44.9%
2025-08-11	365,779	100	823,304	44.4%
2025-08-08	296,152	0	726,740	40.8%
2025-08-07	449,073	0	844,617	53.2%
2025-08-06	468,072	1,801	877,452	53.3%
2025-08-05	850,491	15,776	1,611,416	52.8%
2025-08-04	2,106,729	6,270	3,591,014	58.7%
2025-08-01	2,016,695	5,940	3,035,436	66.4%
2025-07-31	1,474,847	0	2,430,622	60.7%
2025-07-30	489,268	56	1,010,364	48.4%
2025-07-29	708,741	660	1,471,735	48.2%
2025-07-28	709,709	122	1,144,796	62.0%
2025-07-25	424,209	0	793,872	53.4%
2025-07-24	482,292	0	791,304	60.9%
2025-07-23	444,114	0	861,551	51.5%
2025-07-22	599,218	200	1,373,171	43.6%
2025-07-21	427,224	0	1,231,503	34.7%
2025-07-18	492,018	0	1,083,534	45.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE